Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

FMT-CHECKPOINT

A Pilot Study of the Efficacy and Safety of Faecal Microbiota Transplant for the Treatment of Immune Checkpoint Inhibitor Colitis (ACTRN12624000120572)

Currently recruiting

FORMaT

A multi-centre, randomised, multi-arm, adaptive platform trial in people with or without cystic fibrosis Finding the Optimal Regimen for Mycobacterium abscessus Treatment [FORMaT] (NCT04310930)

Currently recruiting

FORTE F8394-201

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations (NCT05503797)

Currently recruiting

FpA-AS-30094

A randomised, double-blind, multicentre, Active-controlled, parallel-group study to evaluate the efficacy and safety of fluticasone proprionate/alburterol sulfate fixed-dose combination on severe asthma exacerbations in patients with Asthma (NCT06052267)

Currently recruiting

FRAIL-AS

Frailty response in patients with aortic stenosis undergoing transcatheter aortic valve implantation; a cluster randomised controlled trial (ACTRN12624000318583)

Currently recruiting

FRAIL-M

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)

Currently recruiting

FRONTIER-AP

FRONTIER-AP: Randomized controlled trial of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion (ACTRN12621001746820)

Currently recruiting

FUNCTIAN

Functional Connectivity-informed Individualised Transcranial Magnetic Stimulation Therapy for Anorexia Nervosa (FUNCTIAN) – An Open-Label Proof of Concept Study (ACTRN12623001146684)

Currently recruiting

GAIN

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants with Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation (NCT06732180)

Currently recruiting

GB261-001

A Phase I/II, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GB261-001) (NCT04923048)

Currently recruiting

GCT3013-03/EPCORE CLL-1

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)

Currently recruiting

GENENTECH GO39775

An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of Cevostamab (BFCR4350A) in patients with relapsed or refractory multiple myeloma (NCT03275103)

Currently recruiting

GENMAB GCT3014-01

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (NCT04824794)

Currently recruiting

GNIA-001

An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (NCT05947656)

Currently recruiting

GO41751

A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER (NCT04468607)

Currently recruiting

GO42144

A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION (NCT04449874)

Currently recruiting

GO42552

AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLUS DARATUMUMAB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (CAMMA 1) (NCT04910568)

Currently recruiting

GO43073

A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (NCT05243342)

Currently recruiting

GO43979

AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (GO43979) (NCT05927571)

Currently recruiting

GO43980

A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (GO43980) (NCT05646836)

Currently recruiting
12 13 14 15 16